Actinium Pharmaceuticals Changes Auditors

Summary

Actinium Pharmaceuticals fired Marcum LLP as its independent registered public accountant on May 8, 2025, and appointed CBIZ CPAs with audit committee approval. Previously, Marcum issued unqualified opinions for fiscal years ending December 31, 2023, and 2024, without reporting disputes or adverse opinions.Reuters

Impact Analysis

The change in auditors is a company-level event, indicating potential shifts in financial reporting practices or corporate governance at Actinium Pharmaceuticals. This move might raise investor concerns regarding transparency and audit quality, especially amid ongoing legal issues regarding FDA approval misrepresentation for its drug candidate Iomab-B.Reuters+ 2 Direct impacts may include increased scrutiny on financial statements and operational practices. Indirect effects could involve shifts in investor sentiment, potentially impacting stock prices. Investors should monitor subsequent audit quality and disclosures for signs of improved or deteriorated financial practices. Opportunities may arise from identifying undervalued shares if transparency improves or if the new auditor enhances confidence in financial reporting. Conversely, risks include potential financial irregularities impacting stock value.